11/14
12:07 pm
fulc
Fulcrum Therapeutics, Inc. (NASDAQ: FULC) had its "sector perform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $4.00 price target on the stock.
Report
Fulcrum Therapeutics, Inc. (NASDAQ: FULC) had its "sector perform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $4.00 price target on the stock.
11/14
12:07 pm
fulc
Fulcrum Therapeutics, Inc. (NASDAQ: FULC) had its "sector perform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $4.00 price target on the stock.
Report
Fulcrum Therapeutics, Inc. (NASDAQ: FULC) had its "sector perform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $4.00 price target on the stock.
11/14
11:21 am
fulc
Rating for FULC
Low
Report
Rating for FULC
11/14
11:21 am
fulc
Rating for FULC
Low
Report
Rating for FULC
11/14
08:15 am
fulc
Fulcrum Therapeutics, Inc. (NASDAQ: FULC) had its "neutral" rating re-affirmed by analysts at HC Wainwright. They now have a $4.00 price target on the stock.
Medium
Report
Fulcrum Therapeutics, Inc. (NASDAQ: FULC) had its "neutral" rating re-affirmed by analysts at HC Wainwright. They now have a $4.00 price target on the stock.
9/13
09:31 am
fulc
Rating for FULC
Medium
Report
Rating for FULC
9/13
09:31 am
fulc
Rating for FULC
Medium
Report
Rating for FULC
9/13
07:59 am
fulc
Fulcrum Therapeutics, Inc. (NASDAQ: FULC) was downgraded by analysts at HC Wainwright from a "buy" rating to a "neutral" rating. They now have a $4.00 price target on the stock, down previously from $17.00.
Medium
Report
Fulcrum Therapeutics, Inc. (NASDAQ: FULC) was downgraded by analysts at HC Wainwright from a "buy" rating to a "neutral" rating. They now have a $4.00 price target on the stock, down previously from $17.00.
9/12
04:36 pm
fulc
Fulcrum Therapeutics, Inc. (NASDAQ: FULC) was downgraded by analysts at Royal Bank of Canada from an "outperform" rating to a "sector perform" rating. They now have a $4.00 price target on the stock, down previously from $15.00.
High
Report
Fulcrum Therapeutics, Inc. (NASDAQ: FULC) was downgraded by analysts at Royal Bank of Canada from an "outperform" rating to a "sector perform" rating. They now have a $4.00 price target on the stock, down previously from $15.00.
9/12
04:36 pm
fulc
Fulcrum Therapeutics, Inc. (NASDAQ: FULC) was downgraded by analysts at Royal Bank of Canada from an "outperform" rating to a "sector perform" rating. They now have a $4.00 price target on the stock, down previously from $15.00.
High
Report
Fulcrum Therapeutics, Inc. (NASDAQ: FULC) was downgraded by analysts at Royal Bank of Canada from an "outperform" rating to a "sector perform" rating. They now have a $4.00 price target on the stock, down previously from $15.00.